ZTS Stock Analysis: Buy, Sell, or Hold?
ZTS - ZOETIS INC.
$74.25
-0.09 (-0.13%)
▼
5d:
-14.96%
30d:
-38.52%
90d:
-40.91%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Distribution
ZTS is up 4.2% this week, but smart money is buying puts. Top strike: $105 2026-06-18 with 1,103 OI. Put ratio: 63% View Scanner →
Strength: 3.4/10
Get Alerted When ZTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called ZTS this week
67% bullish • 1 bearish
67% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ZTS is down 15.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ZTS is down 15.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$168.62
Based on 6.1% avg growth
INTRINSIC VALUE TODAY
$104.70
29.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZTS is currently trading at $74.25, which is considered oversold relative to its 30-day fair value range of $93.39 to $125.50. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.9) compared to its historical average (16.8). Remarkably, the market is currently pricing in an annual earnings decline of 16.1% over the next few years. This pessimistic expectation contrasts with the company's recent 6.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ZTS is in a strong downtrend. The price is currently testing key support at $74.29. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $130.82 (+76.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZTS is in a strong downtrend. The price is currently testing key support at $74.29. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $130.82 (+76.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$93.39 -
$125.50
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding ZTS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 76.0% below Wall St target ($130.82)
- WARNING: Recommendation downgraded due to -15.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$93.39 -
$125.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$74.29
Resistance Level
$116.25
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.95
Wall Street Target
$130.82
(+76.0%)
Revenue Growth (YoY)
2.9%
Earnings Growth (YoY)
6.0%
Profit Margin
28.0%
Valuation Discount vs History
-16.1% cheaper
PE vs Historical
10.0 vs 16.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-16.1%
(market-implied from PE analysis)
1-Year Target
$66.91
(-10%)
2-Year Target
$60.22
(-19%)
3-Year Target
$54.19
(-27%)
3-Yr Target (if PE normalizes)
(PE: 10→17)
$91.47
(+23%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 8.2%)
$208.72
(+181%)
Base:
(SPY PE: 10.0, Growth: 8.2%)
$94.26
(+27%)
Bear:
(PE: 8.5, Growth: 8.2%)
$80.12
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 12.19 | Current EPS (TTM): $6.10
Bull Case
$100.12
(+35%)
Analyst growth 22.4%, PE expands to 13.4
Base Case
$91.02
(+22%)
Market implied 22.4%, PE stable at 12.2
Bear Case
$50.55
(-32%)
Severe decline -20.0%, PE contracts to 10.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.0 to 16.8
Stabilization Target:
$125.47
(+68.8%)
PE Expansion Potential:
+68.8%
Share & Embed Analysis
Last updated: May 14, 2026 3:40 PM ET
Data refreshes hourly during market hours. Next update: 4:40 PM
Data refreshes hourly during market hours. Next update: 4:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZTS showing a specific setup today?
Insider Activity (6 Months)
5
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Gilbert Ray Cisneros, Jr.
SELL
2026-03-13
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$40 | 57 HOLD |
Advanced ZTS Option Strategies
Professional options setups generated by AI based on today's ZTS price and gamma walls.
